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Abstract
Purpose This study investigated the effect of the “Screening for Distress and Referral Need” (SDRN) process (completing a
screening instrument; patient-caregiver discussion about the patient’s responses, regardless of distress level, and possible referral
to specialized care), implemented in Dutch oncology practice on patient-reported outcomes (PROs).
Methods A non-randomized time-sequential study was conducted to compare two cohorts. Cohort 1 respondents (C1) were
recruited before and cohort 2 respondents (C2) after SDRN implementation in nine Dutch hospitals. Participants completed the
EORTC-QLQ-C30, HADS, Patient Satisfaction Questionnaire-III, and the Distress Thermometer and Problem List (DT&PL).
Descriptive analyses and univariate tests were conducted.
Results C2 respondents (N = 422, response = 54%) had significantly lower mean scores on the practical (t = 2.3; p = 0.02), social
(t = 2.3; p = 0.03), and emotional PL domains (t = 2.9; p = 0.004) compared with C1 (N = 518, response = 53%). No significant
differences were found on quality of life, anxiety, depression, satisfaction with care, distress level, the spiritual and physical PL
domains, or on referral wish.
Conclusions After implementation of SDRN, patients report significantly fewer psychosocial (practical, social, and emotional)
problems on the DT/PL but responses on the other patient-reported outcomes were comparable. These results add to the mixed
evidence on the beneficial effect of distress screening. More and better focused research is needed.
Keywords Effect study . Distress screening . Patient-reported outcomes . DT&PL
Introduction
Distress screening guidelines have been developed to ensure
that medical specialists and nurses gain insight into distress
and cancer-related problems of cancer patients regularly and
that timely and justified referral of distressed patients to addi-
tional professional care takes place [1–4]. The aim is to
prevent worsening of and/or treat cancer-related distress and
problems and to maintain or improve quality of life (QoL).
However, the results reported in the literature on the effect of
distress screening on patient-reported outcomes (PRO) are
inconsistent. Results vary from significant benefits on primary
outcomes, such as (aspects of) QoL, depression, anxiety, and/
or symptom burden (e.g., [5–8]), and secondary outcomes
such as patient-care provider communication and quality of
care, to no significant effects on such outcomes (e.g., [9, 10]).
No studies reported a negative effect of distress screening.
The varying results may be due firstly to the differences in
study design. Some studies used a randomized controlled de-
sign while others used a cross-sectional cohort pre-post imple-
mentation sequential design or an observational design.
Secondly, the instruments used vary between studies. Some
studies used a non-cancer-related questionnaire like the
Hospital Anxiety and Depression Scale [11, 12], while others
used a cancer-specific questionnaire like the European
Organization for Research and Treatment of Cancer -
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Quality of Life Questionnaire (EORTC-QLQ) [13] or the
Functional Assessment of Cancer Therapy-General (FACT-
G) [14]. Some recent studies used the instrument used for
screening as outcome measure [6–8]. To our knowledge, only
one study [8] has reported results on the Distress
Thermometer and the Problem List (DT&PL) as outcome
measure although this instrument is used for screening world-
wide [15, 16].
Thirdly, differences in results of the effect of distress
screening could be explained by differences in the distress
screening procedure used. The method used to screen patients
reportedly varies from only informing responsible medical
specialists that a certain patient has a score above a cut-off
to a more comprehensive process including triage. More stud-
ies using a more comprehensive distress screening process
including triage found positive effects for patients than studies
that examined a simple process consisting of patients complet-
ing a screening instrument that was made available to a
healthcare provider who then decided what to do with it.
The extent to which healthcare providers actually used patient
information on a screening instrument during consultations or
if they discussed responses on a completed screening instru-
ment with all or some patients, such as only those having a
score above a cut-off, remains unclear in most of the studies
published [4].
In the Netherlands, the Comprehensive Cancer
Organisation Netherlands, location Groningen (IKNL-G), im-
plemented a process of “Screening for Distress and Referral
Need” (SDRN) in routine clinical practice of general hospitals
and one university medical center in the IKNL-G’s catchment
area together with professionals in these hospitals. Previously,
in none of these hospitals did SDRN or another form of dis-
tress screening take place. The SDRN process involves (1)
regular completion of the Dutch version of the DT&PL by
patients during (curative or palliative) treatment and follow-
up; (2) discussion of DT&PL responses between care provider
and patient, regardless of the DT-score being below or above
the cut-off; (3) referral to psychosocial and/or allied healthcare
providers based on the DT&PL responses and the discussion.
The Dutch guideline advises that this comprehensive distress
screening process takes place during a patient’s hospital visit
with either the oncologist or the nurse at least every 3 months
during treatment and follow-up [4]. Additionally, providing
information about the goal of SDRN and the DT&PL and
about the expertise of psychosocial and allied healthcare pro-
fessionals to whom the patient could be referred to was con-
sidered essential [17, 18].
The aim of the current 2-cohort pre-post implementation
study is to examine the effect of SDRN implemented in daily
practice in hospitals on patients’ cancer-related distress, prob-
lems, and referral wish, on patients’QoL, anxiety, and depres-
sion, and on their satisfaction with care. We hypothesize that
the effects are positive.
Method
Design
This study employed a comparative 2-cohort pre-post imple-
mentation sequential design.
Participants
Eligible patients were newly diagnosed patients, and patients
in treatment or follow-up who visited a medical, surgical,
gynecological, or urological outpatient clinic of one of the
nine hospitals willing to implement SDRN and to participate
in the study. Other inclusion criteria were that patients had to
be aware of their cancer diagnosis and treatment plan; 18 years
or older; and cognitively and physically able to answer ques-
tionnaires in the Dutch language. Patients with a psychiatric
diagnosis were excluded.
Procedure
Cohort 1: The first cohort of cancer patients (C1) was recruit-
ed between January 2007 and December 2010 in nine hospi-
tals in the Netherlands. These hospitals had decided to imple-
ment the SDRN process; C1 was recruited pre-implementa-
tion. Hospitals were given a pre-determined number of pack-
ages consisting of written information about the study, the
questionnaire, an informed consent form, and a pre-franked
return envelope. The number of packages varied between hos-
pitals from 30 to 200 depending on the number of cancer
patients newly diagnosed per year in each particular hospital
(Dutch Cancer Registry, IKNL). Nurses and medical special-
ists informed all eligible patients about the goal of the study
during a regular outpatient clinic medical visit and gave them
the package. Informing patients and handing out packages
took between 2 and 4 weeks. Patients were asked to complete
the questionnaire at home and send it in the supplied pre-
franked envelop to IKNL-G. For reasons of anonymity, no
information was given to IKNL-G by the hospitals about the
patients approached to participate, and thus how many pa-
tients accepted the package.
Once the pre-determined number of packages was
handed out, implementation of SDRN started according
to a pre-developed roadmap including procedure and ma-
terials in the participating hospitals. In short, IKNL-G
representatives approached hospitals and informed stake-
holders in oncology care about the importance of SDRN,
supported implementation, provided centralized project
management, and organized mono- and multidisciplinary
meetings for professionals of the hospitals to share expe-
riences with implementation and execution of SDRN in
clinical practice. Hospitals were urged to appoint a team
leader and to form a multidisciplinary team [17].
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Cohort 2: After SDRN had been implemented for at least a
year according to a hospital, the second cohort (C2) was re-
cruited from the first nine hospitals that met these criteria.
Procedure and inclusion criteria were equal to cohort 1, with
one exception. The (written) information about the study that
C2 participants received was slightly different. C1 respon-
dents were informed that a quality improvement project in-
volving screening for distress was going to be implemented in
the hospital and that they were invited to participate in a study
assessing their QoL and satisfaction with care received before
implementation. C2 respondents were informed that SDRN
had been implemented and that we invited them for a study
assessing their QoL and satisfaction with care received after
implementation. Both groups were informed about the goal of
SDRN. There was no overlap in patients between cohorts.
The medical ethical committee of the University Medical
Centre Groningen decided that no approval was needed for the
study. The study was performed according to the ethics com-
mittees of the participating hospitals and the Helsinki
Declaration.
Instruments
Participants completed questions on socio-demographic (age;
gender; highest education completed (low (elementary or low
vocational school), middle (secondary or middle vocational
education), high (high vocational or university)); having chil-
dren (yes or no, living at home or out of the house); and
illness-related characteristics (date of diagnosis, cancer type,
type of treatment, and treatment phase (watchful waiting, un-
der active treatment, or follow-up)). Types of treatment were
dichotomized into non-intensive (surgery only, radiotherapy
only, and watchful waiting) and intensive treatment (all other
treatment modalities). Based on the type of cancer and treat-
ment, a medical oncologist placed patients in a curative or a
palliative treatment intent group.
The Dutch Distress Thermometer and Problem List
(DT&PL) [15] was used as instrument in the SDRN pro-
cess and as patient-reported outcome measure. Patients
indicated their cancer-related level of distress during the
last week on the DT on an 11-point Likert scale from 0
(not distressed) to 10 (extremely distressed). The cut-off
score found was 5 (sensitivity = 85%; specificity = 67%).
On the 47-item PL (α = .90), patients could indicate
whether they experienced problems in the following do-
mains: practical (7 items (α = .60)); social (3 items (α =
.75)); emotional (10 items (α = .80)); spiritual (2 items (α
= .64)); and physical (25 items (α = .74)). The scoring
scale on a problem item ranges from 0 (no, not a problem)
to 1 (yes, very mildly troubled) to 10 (yes, extremely
much troubled). Five PL domain summary scores were
computed by taking the total score of the items in each
domain. Possible ranges depended on the number of items
in each domain and varied from 0–20 to 0–250. Lastly,
respondents indicated if they wanted a referral for the
problems they experienced (no, maybe, or yes).
The European Organization for Research and Treatment of
Cancer, Quality of Life Questionnaire-C30 (EORTC-QLQ-
C30) [13], a frequently used (nationally and internationally),
valid and reliable, self-report, 30-item questionnaire was used
to assess cancer patients’ quality of life. The EORTC-QLQ-
C30 consists of the five functioning subscales: physical (5
items (α = .71)), emotional (4 items (α = .80)), role (2 items
(α = .52)), social (2 items (α = .77)), and cognitive function-
ing (2 items (α = .73)); and the global quality of life subscale
(2 items (α = .89)). Subscale scores were computed and trans-
formed to a range from 0 to 100 according to the manual.
Higher scores on the functioning and global QoL subscales
indicate a higher QoL.
The 14-item Hospital Anxiety and Depression Scale
(HADS) [11, 12] is a widely used tool to measure mild mood
disorders in non-psychiatric patients. It consists of the two 7-
item subscales anxiety (α = .83) and depression (α = .82).
Patients are asked to indicate how they feel during the last 2
weeks on a 4-point scale ranging from 0 to 3. Subscale scores
range from 0 to 21 and the total score from 0 to 42. Higher
scores indicate higher symptom severity.
The 42-item Patient Satisfaction Questionnaire-III
(PATSAT) [19] assesses patient satisfaction with oncological
care on four aspects: technical quality (10 items (α = .74)),
interpersonal behavior (14 items (α = .89)), accessibility (12
items (α = .76)), and general satisfaction (6 items (α = .92)).
Total satisfaction represents the score of all questions. Patients
could indicate their agreement on a 5-point scale ranging from
agree completely (1) to disagree completely (5). After sum-
mation of items, subscale scores are transformed into a range
from 0 to 100. Higher scores indicate higher satisfaction.
Analysis
Descriptive analyses were conducted for the socio-
demographic and illness-related characteristics, and for the
patient-reported outcome measures. T tests (for continuous
variables) and chi-square tests (categorical variables) were
used to compare C1 with C2 on patient’ characteristics and
the outcome measures. Effect sizes (Cohen’s d) were comput-
ed when groups were found to differ significantly to examine
if these differences were clinically relevant. Cohen’s d < 0.2
were considered negligible, those between 0.2 and 0.49 small,
those between 0.50 and 0.79 moderate, and those > 0.80 large
[20]. At the request of pastoral workers, two hospitals did not
use the two sub-items in the spiritual domain for C2 respon-
dents, thus reducing the number of respondents for this do-
main with N = 85. Analyses were performed with SPSS ver-
sion 23.
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Test value p value
Age (mean ± SD) (range) 59.8 ± 11.5 (27.5–89.0) 59.3 ± 10.5 (29.9–87.5) t = 0.74 0.46
Missing (N) 7 5
Gender (N(%)) X2 = 8.8 0.003
Men 138 (27) 82 (19)
Women 380 (73) 360 (81)
Education (N(%)) X2 = 1.3 0.52
Low 131 (26) 103 (24)
Middle 246 (48) 203 (47)
High 131 (26) 125 (29)
Missing 10 11
Having children (N(%)) X2 = 0.06 0.8
No 77 (15) 63 (14)
Yes 441 (85) 378 (86)
Missing 0 1
Children living at home (N(%)) X2 = 2.9 0.09
No 314 (68) 234 (62)
Yes 151 (33) 144 (38)
Missing 53 64
Type of cancer (N(%)) X2 = 32.1 < 0.001
Breast 304 (59) 306 (69)
Digestive 77 (15) 32 (7)
Skin 25 (5) 9 (2)
Hematologic 22 (4) 24 (5)
Gynecologic 17 (3) 15 (3)
Sarcoma/bone 16 (3) 8 (2)
Prostate 14 (3) 19 (4)
Lung 14 (3) 19 (4)
Other 24 (5)† 9 (2)††
Missing 5 1
Time since diagnosis
(in years) (mean ± SD) (range)
2.2 ± 3.4 (0.0–29) 1.2 ± 1.9 (0.0–19) t = 5.6 < 0.001
Missing (N) 23 42
Treatment type (N(%)) X2 = 12.7 0.18
Surgery 98 (19) 72 (16)
Surgery + radiotherapy 86 (17) 89 (20)
Surgery +chemotherapy 105 (21) 72 (16)
Surgery + radiotherapy + chemotherapy 128 (25) 132 (30)
Surgery + immunotherapy and/or hormonal therapy 8 (2) 14 (3)
Radiotherapy 7 (1) 7 (2)
Chemotherapy 49 (10) 30 (7)
Radiotherapy + chemotherapy 21 (4) 19 (4)
Immunotherapy and/or hormonal therapy 1 (0) 0 (0)
Watchful waiting 4 (1) 3 (1)
Missing 11 4
Treatment intensity (N (%)) X2 = 1.1 .29
Non-intensive (surgery only, RT only, watchful waiting) 109 (22) 82 (19)
Intensive 398 (79) 356 (81)
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Results
A total of 518 respondents participated in C1 (response =
53%) and 442 respondents in C2 (response = 54%).
Response rates were comparable between hospitals. Table 1
shows patient’ characteristics and comparisons between the
two cohorts. Cohorts were equal with respect to age, education
level, having children, children living at home, treatment type,
intensity, and phase. Groups differed significantly in gender
(X2 = 8.8; p = 0.003), type of cancer (X2 = 32.1; p ≤ 0.001),
time since diagnosis (t = 5.6; p ≤ 0.001), and treatment intent
(X2 = 7.1; p = 0.008). In comparison to C1, more C2 respon-
dents were female, and more were diagnosed with breast can-
cer while fewer with digestive cancer. Time since diagnosis
was significantly shorter in C2, and fewer C2 respondents
were treated with a palliative intent.
DT&PL
DT mean scores were not significantly different between the
cohorts nor were percentages scoring under or above the cut-
off (Table 2). Compared with C1 respondents, C2 respondents
had significantly lower mean scores on problems in the prac-
tical (t = 2.3; p = 0.02; Cohen’s d = 0.15), social (t = 2.3; p =
0.03; Cohen’s d = 0.15), and emotional (t = 2.9; p = 0.004;
Cohen’s d = 0.19) domains. Mancova’s correcting for differ-
ences between cohorts (sex, type of cancer, time since diag-
nosis, and treatment intent) resulted in comparable findings
between cohorts for the practical (p = 0.008), social (p =
0.038), and emotional (p = 0.006) domains. Due to the large
overlap between sex and cancer type, the analyses were also
performed without the type of cancer; results between groups
were comparable: practical p = 0.007; social p = 0.038; and
emotional p = 0.005.
No significant difference was found between the cohorts in
responses on the referral wish question (Table 2).
QoL, anxiety, depression, and patients’ satisfaction
with care
No statistically significant differences were found between C1
and C2 on any of these outcome measures (Table 3).
Discussion
The present comparative two-cohort pre-post implementation
sequential study examined the effects on PRO’s of a process
of distress and referral need screening (SDRN) implemented
in real-world oncology practice. After SDRN had been imple-
mented in clinical practice, cancer patients reported signifi-
cantly lower symptom presence and severity in the practical,
social, and emotional domains of the PL than before SDRN
had been part of standard care. These results suggest a bene-
ficial effect. However, no differences were found between the
two patient groups in the level of distress, the spiritual and
physical domains, and in referral wish, in QoL, anxiety, and
depression, or in patients’ satisfaction with care, indicating no
beneficial effects of SDRN. Consequently, our results add to
the mixed results reported in the literature that vary between a
beneficial effect on patients’ well-being, symptom burden,
and on quality of care process measures [5–8] and no effect
of distress screening on such outcomes [9, 10].
Interestingly, we did find significant differences in the psy-
chosocial domains of the DT&PL, the instrument used for
screening and communication in the SDRN process. This re-
sult is comparable to three studies with a similar two-cohort
pre-post implementation sequential design that also used the






Test value p value
Missing 11 4
Treatment intent (N(%)) X2 = 7.1 0.01
Curative 429 (85) 396 (90)
Palliative 78 (15) 42 (10)
Missing 11 4
Treatment phase (N(%)) X2 = 1.0 0.61
Watchful waiting 2 (0.4) 3 (0.7)
Under active treatment 253 (50.3) 203 (46.7)
Follow-up 258 (49.3) 229 (52.6)
Missing 5 7
† 10 liver, 9 urologic, 3 head/neck, 1 brain, 1 unspecified
†† 3 liver, 2 urologic, 2 head/neck, 1 brain, 1 unspecified
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symptoms and concerns as outcome measure [6–8]. A possi-
ble explanation is that completing and discussing the results of
a screening instrument helped C2 respondents with their psy-
chosocial problems. Talking with a caregiver about a possible
referral and receiving extra information about self-
management strategies might be enough for some patients to
reduce the presence and severity of their distress. However,
differences appear to be clinically not very relevant.
Regretfully, no difference was found on the other outcome
measurements. It may well be that questionnaires designed to
examine group-level differences (e.g., EORTC-QLQ-C30)
and non-cancer-related questionnaires (e.g., HADS) measure
a different and broader construct than what patients initially
experience as the added value of a process of SDRN, namely
providing clearer opportunity for discussion of cancer-specific
psychosocial problems and the possibility to be referred for
further care.
The mixed results in the present study raise the question not
only if the study design chosen or the instrument used is the
optimal choice to demonstrate an effect of distress screening
Table 2 Descriptives on the
DT&PL and comparisons
between cohorts 1 (pre-
implementation) and 2 (post-
implementation)
C1 C2 Test value p value
Mean (SD) N Mean (SD) N
DT 3.8 (2.6) 458 3.5 (2.5) 415 t = 1.6 0.1
Cut-off (N(%)) X2 = 2.7 0.1
< 5 272(59) 269 (65)
≥ 5 186(41) 146 (35)
Practical 4.6 (7.4) 493 3.5 (6.3) 431 t = 2.3 0.02
Social 1.4 (3.7) 501 0.9 (3.2) 432 t = 2.3 0.03
Emotional 13.3 (17.3) 485 10.2 (14.4) 424 t = 2.9 0.004
Spiritual 1.2 (3.0) 494 0.8 (2.8) 355 t = 1.8 0.07
Physical 28.4 (29.9) 471 25.7 (27.9) 419 t = 1.4 0.16
Referral wish (N(%)) X2 = 3.3 0.19
No 330 (66) 282 (66)
Maybe 105 (21) 77 (18)
Yes 64 (13) 71 (17)
N varies due to missing data




sons between cohorts 1 (pre-
implementation) and 2 (post-
implementation)
C1 C2 t test p value
Mean (SD) N Mean (SD) N
EORTC-OLQ-C30
Global 73.2 (20.1) 508 72.9 (19.9) 437 − .25 0.80
Physical 79.0 (19.0) 501 79.1 (18.8) 432 .08 0.94
Role 71.6 (28.0) 505 73.0 (27.6) 434 .78 0.44
Emotional 82.7 (18.6) 502 82.8 (18.2) 433 .07 0.95
Cognitive 83.3 (20.2) 507 82.8 (20.1) 434 − .44 0.66
Social 83.0 (22.1) 506 84.3 (20.0) 438 .95 0.34
HADS
Total 8.2 (6.9) 497 8.0 (6.8) 423 .54 0.59
Anxiety 4.7 (3.6) 504 4.5 (3.7) 429 .85 0.40
Depression 3.5 (3.6) 507 3.5 (3.7) 433 .27 0.79
Patient Satisfaction Questionnaire-III
Total 80.7 (13.4) 503 81.1 (12.8) 436 .55 0.58
Technical quality 78.8 (15.8) 504 78.6 (15.4) 436 − .30 0.76
Interpersonal behavior 83.9 (15.4) 508 84.4 (14.9) 437 .61 0.54
Accessibility 78.6 (14.4) 502 79.4 (13.7) 433 .99 0.32
General satisfaction 81.1 (18.9) 506 80.9 (19.3) 435 − .08 0.94
N varies due to missing data
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but also if it is realistic to expect that distress screening in itself
can result in improvement in patients’ functioning. As to this
last point, we did find that more frequent and fuller exposure
to SDRN is positively associated with patients’ satisfaction
with distress screening [18]. This would argue for careful as-
sessment of how systematic the SDRN process steps are per-
formed during treatment and follow-up. Distress screening is
designed simply to recognize cancer patients’ psychosocial
problems and possibly refer them to specialized care.
Whether patients who receive a referral actually take up treat-
ment has not yet been researched to date nor has it been
researched what the effect is of the treatment that referred
patients do undergo. This is unfortunate, as supportive inter-
ventions from psychosocial and allied health care profes-
sionals have been reported to be effective in terms of QoL,
anxiety, and depression and patients’ functioning [21–23] and
exactly those correctly identified patients in need may benefit
from supportive interventions [24]. Future research should
longitudinally study patients who do want a referral separately
from those who do not. As not all patients who receive a
referral actually follow through with the referral, patients
who do take up treatment should be followed separately from
those who do not. In addition to researching the effects of
distress screening, referral, and take up of services, future
studies should also investigate possible reduction in utilization
of medical services and associated costs [25].
The current study has the following limitations. First is the
design of the study. To examine whether a distress screening
process affects outcomes such as patient functioning or refer-
ral, a randomized controlled trial may be a more robust type of
research. In a clinical situation, randomizing patients is uneth-
ical and keeping patients unaware of a difference in
(treatment) approach hardly possible. The advantage of our
design is the representation of “real-world” everyday clinical
practice in which SDRN is implemented. An RCT is an arti-
ficially controlled approach to everyday clinical practice.
However, our study design may mean that the effects we
found cannot be completely attributed to SDRN but could
have resulted from other causes or circumstances.
This study was also not a longitudinal study. As mentioned
above, future research should follow patients longitudinally to
measure effects on the PRO’s of psychosocial and/or allied
care interventions to which patients were referred and possibly
accepted as a result of the SDRN process.
Second, the response rate was 53% in C1 and 54% in C2,
which is comparable to psychosocial studies in oncology [26]
but lower than the mean response rate of 70% reported in a
recent systematic review [27]. We cannot compare responders
to non-responders due to study design. Therefore, we cannot
be certain whether respondents are a selection of the total
group. There are many reasons why people may decide not
to complete a questionnaire, for example not only that they
were too distressed but also that they were not distressed at all.
This and also other reasons for not participating apply equally
to both cohorts. Still this may have affected the representative-
ness and generalizability. However, this study was conducted
in nine hospitals and included patients with varying socio-
demographic and illness-related characteristics.
Patients in the cohorts differed in some respects. Compared
with C1, more C2 respondents were female, more had breast
and fewer digestive cancers, time since diagnosis was shorter,
and fewer were treated with a palliative intent. Some of these
characteristics have been associated with decreased function-
ing (female gender, shorter time since diagnosis) [28–30] or
were found to be unrelated (treatment intent, breast or diges-
tive cancer) [31]. Given these demographic differences, one
would expect to find higher distress in C2 patients.
Remarkably, we found slightly lower distress in C2 compared
with that in C1, which is promising.
In conclusion, in hospitals that had implemented SDRN,
patients report significantly lower presence and severity of
problems in the psychosocial (practical, social, and emotional)
domains, the domains for which distress screening has been
developed and advocated. This is promising and could stimu-
late care professionals to implement or improve a SDRN pro-
cess. However, better-designed and more focused studies are
needed.
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